Interleukin-12 Antagonist
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Interleukin-12 Antagonist
Interleukin-12 Antagonist drugs represent a targeted approach to modulating immune responses by blocking the signaling pathways of IL-12 and IL-23 cytokines. These cytokines play a crucial role in the pathogenesis of various inflammatory and autoimmune diseases, particularly those driven by T-helper 1 (Th1) and T-helper 17 (Th17) cell responses. By inhibiting IL-12 and IL-23, these therapies effectively dampen the inflammatory cascade, leading to clinical improvement in affected patients.
The primary approved indication for this class of drugs is in dermatological and rheumatological conditions, with STELARA (ustekinumab) by Johnson & Johnson being the first-in-class agent, approved in 2009 for plaque psoriasis and psoriatic arthritis. The success of STELARA has paved the way for further development and has recently seen the emergence of biosimilar versions, indicating a maturing market.
The field is evolving with the introduction of biosimilars, offering increased competition and potentially broader patient access. Future directions may involve exploring new indications where IL-12/IL-23 signaling is implicated and potentially developing next-generation antagonists with enhanced selectivity or efficacy profiles.
7 FDA-approved Interleukin-12 Antagonist drugs, including OTULFI, with 30 active Phase 3 trials across 7 indications from 5 active sponsors. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Interleukin-12 Antagonist Drugs
7 totalThe Interleukin-12 Antagonist landscape is currently defined by the pioneering drug STELARA (ustekinumab), launched by Johnson & Johnson in 2009 for plaque psoriasis and psoriatic arthritis. As the first-in-class therapy, STELARA established the efficacy of targeting the p40 subunit shared by IL-12 and IL-23. Its success validated the therapeutic potential of this mechanism, leading to its approval across multiple autoimmune conditions. The subsequent years saw STELARA solidify its position as a key treatment option. Differentiation within the Interleukin-12 Antagonist class is primarily observed through the emergence of biosimilar versions of ustekinumab. These include WEZLANA (ustekinumab-auub) from Amgen, PYZCHIVA (ustekinumab-ttwe) from SAMSUNG BIOEPIS CO LTD, OTULFI (ustekinumab-aauz) from Fresenius Kabi, YESINTEK (ustekinumab-kfce) from BIOCON BIOLOGICS INC, and STARJEMZA (ustekinumab-hmny) from BIO-THERA SOLUTIONS LTD, all approved between 2023 and 2025. These biosimilars are designed to be highly similar to the reference product, STELARA, in terms of safety, efficacy, and quality, offering comparable treatment options. Today, the Interleukin-12 Antagonist class, led by STELARA and its biosimilars, is a well-established treatment option for moderate to severe plaque psoriasis and psoriatic arthritis, often used in patients who have had an inadequate response to other therapies. The recent influx of biosimilar approvals signifies a significant shift towards increased market competition and patient access. This dynamic suggests a maturing market where cost-effectiveness and physician/patient choice will play increasingly important roles in therapeutic selection.
Interleukin-12 Antagonist Indications in Trials
Active industry trialsThe active Phase 2 and 3 pipeline for Interleukin-12 Antagonist therapies shows significant activity concentrated in key inflammatory conditions. Crohn's Disease currently leads with two active trials, alongside Plaque Psoriasis, which also has two active trials. Other indications with notable pipeline presence include Arthritis, Juvenile, Crohn Disease, Colitis, Ulcerative, and Moderate to Severe Plaque Psoriasis, each with at least one active trial, indicating a sustained interest in leveraging this mechanism for gastrointestinal and dermatological inflammatory disorders. The expansion frontier for Interleukin-12 Antagonist drugs extends beyond their established indications, exploring new patient subpopulations and potentially combination regimens. While the provided data focuses on active trials, the presence of multiple indications suggests ongoing efforts to broaden the therapeutic utility of IL-12/IL-23 inhibition. The development of biosimilars also implies that the originator's indication coverage is a benchmark that biosimilar developers aim to match, further solidifying the class's role in these disease areas. Looking ahead to the next 6-12 months, key readouts from ongoing Phase 2 and 3 trials in Crohn's Disease and Plaque Psoriasis will be critical for understanding the continued evolution of this drug class. The presence of seven active Phase 3 trials and one active Phase 2 trial suggests a robust pipeline. However, the success in these areas will determine if the pipeline remains rich or begins to thin, especially as biosimilars gain market share and potentially influence the development of novel agents.
Top Interleukin-12 Antagonist Sponsors
Industry trials, any indicationJanssen Research & Development, LLC, stands as the dominant player in the Interleukin-12 Antagonist space, leading with four active trials. This leadership is directly attributable to their development and commercialization of STELARA, the originator drug. Janssen's extensive experience and established franchise in IL-12/IL-23 inhibition provide a deep well of expertise and a strong foundation for ongoing research and development, including exploring new indications or patient populations. Key challengers in the Interleukin-12 Antagonist arena include UCB Biopharma SRL, AbbVie, Bristol-Myers Squibb, and Takeda, each contributing one active trial to the Phase 2/3 pipeline. These sponsors are likely exploring the therapeutic potential of IL-12/IL-23 antagonism in specific disease areas, potentially seeking to carve out niches or challenge existing treatment paradigms. The presence of multiple sponsors indicates a competitive environment, with both originator-focused and follower strategies at play. The strategic landscape for Interleukin-12 Antagonist drugs is significantly shaped by the biosimilar market. Manufacturers like SAMSUNG BIOEPIS CO LTD, Fresenius Kabi, BIOCON BIOLOGICS INC, and BIO-THERA SOLUTIONS LTD are entering the market with ustekinumab biosimilars, primarily targeting plaque psoriasis and psoriatic arthritis. This dynamic introduces a geographic dimension, with biosimilar development often originating from or targeting emerging markets. Upcoming catalysts include the performance and market penetration of these biosimilars, which could shift the competitive balance and influence investment decisions for both established players and new entrants.
Interleukin-12 Antagonist Phase 3 Readout Calendar Pro
6 Phase 3 trials testing approved Interleukin-12 Antagonist drugs across 5 indications from 3 sponsors. Earliest readout: Q4 2024.
Coverage: trials whose intervention is an approved Interleukin-12 Antagonist drug. Pre-approval candidates with development codes are not yet linked.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.